TL;DR
We analyzed FDA recall records from the openFDA enforcement database. Two numbers stand out for insurance: Class II devices account for about 88% of all 39,539 device recall records, the tier manufacturers most often assume is low-risk, and compounded-drug recalls number 1,211 records. Recall and products-liability exposure concentrates exactly where many operators underinsure it.
2026 data analysis
What FDA recall records reveal about where insurance exposure actually concentrates.
The FDA publishes recall and enforcement records through the openFDA API. We pulled the device and drug enforcement datasets and looked at them through one lens: where does recall and products-liability exposure actually sit, and does it match how operators buy coverage. It usually does not.
Medical device recalls
- 39,539device recall records
- 88%are Class II
- 3,590Class I (most serious)
- +44%recalls 2022 to 2024
Finding 01
Recall exposure lives in Class II, not Class III.
Of 39,539 device recall records in openFDA, 34,923 (88%) are Class II devices, 3,590 are Class I (the most serious category), and only 1,025 are Class III. Class II is the moderate-risk tier that most manufacturers treat as routine, yet it carries the overwhelming majority of recall activity.
The insurance read: a standard products policy with a thin recall extension is sized for the risk profile operators assume they have, not the one the data shows. For device makers, that is the argument for a dedicated recall sublimit and for occurrence-form products coverage that responds to the long claim tail on implantable and long-use Class II devices, rather than a claims-made form that can leave a gap years later.
Recalls also concentrate geographically in the major device clusters, led by California, Massachusetts, Illinois, Pennsylvania, Indiana, New Jersey, Minnesota, and Florida, the same states where GPO and hospital purchase contracts impose the strictest insurance schedules.
Drug & compounding recalls
- 17,816drug recall records
- 1,211compounded-drug recalls
- 1,357sterile-drug recalls
- 64GLP-1 recall records
Finding 02
Compounding recall exposure is real and quantifiable.
The openFDA drug enforcement dataset holds 17,816 recall records, of which 1,211 reference compounded drugs and 1,357 reference sterile products. About 81% are Class II. For 503A pharmacies and 503B outsourcing facilities, that is a concrete counterpoint to the assumption that a recall is a remote event: recall coverage and a products program sized to hospital purchase contracts are load-bearing, not optional.
On the GLP-1 front, the dataset contains 43 semaglutide and 21 tirzepatide recall records (64 combined). That sits alongside the 2025 to 2026 wave of specialty-pharmacy carrier exclusions for non-FDA-approved drugs, which is why GLP-1 compounders should read renewal endorsement schedules line by line rather than assume the products policy still responds.
Methodology
Where the numbers come from.
All figures are counts pulled from the FDA's openFDA enforcement API on July 27, 2026: the device enforcement endpoint and the drug enforcement endpoint. Classification splits (Class I / II / III) are across the full available dataset in each endpoint; the year-over-year device figures are by recall initiation date; the compounded, sterile, semaglutide, and tirzepatide counts are keyword matches on the product description field.
These are FDA recall and enforcement records, not insurance claims, and openFDA notes its data may be incomplete or updated over time. We report the counts as the FDA database presents them and draw the insurance implications from practice. No figures on this page are estimated.
Why operators choose this practice
Life sciences only
Every placement passes through specialty life-sciences underwriters - not a general manufacturer or healthcare desk.
All 50 US states
Programs placed nationally with deep practice content for the 16 states anchoring the major US life-sciences clusters.
End-of-day SLA
Coverage review requests come back the same business day. MSA reads are typically half an hour or less.
Decoder + glossary
Free MSA Decoder, 49-clause glossary, 60+ Q&A library. Designed for CFOs, GCs, and Quality leaders.
Two ways to start
Wherever you are, there is a next step.
Explore on your own
Reviewing a contract or sizing a first program?
Run your sponsor MSA, GPO supplier agreement, or hospital purchase contract through the free tools. No login, no contact, results in about fifteen minutes. Built for founders and earlier-stage operators who want to understand the requirement first.
Talk to a specialist
Scaled operation, a live contract, or a complex program?
Multi-entity structures, high-limit towers, GPO and hospital contract portfolios, transactional and exit diligence. When the program is load-bearing, a specialist reads it clause by clause and rebuilds it to pass. End-of-business-day response.
Coverage review
See whether your recall and products program matches your actual exposure.
Send your current program and the contract requirements you are working against. A specialist returns a clause-by-clause read by end of business day.